{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T04:15:09Z","timestamp":1784175309071,"version":"3.55.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Telofiban is a class of small molecule non-peptide tyrosine derivatives containing RGD sequences. It is the only platelet surface glycoprotein (GP) IIb\/IIIa receptor antagonist (GPI) currently marketed in China. In patients with ST-segment elevation myocardial infarction(STEMI) who receive percutaneous coronary intervention (PCI) with a heavy thrombotic load, postoperative intravenous tirofiban can prevent complications of myocardial ischemia due to sudden coronary artery occlusion. With the increase in the clinical use of tirofiban, the number of adverse reactions related to thrombocytopenia induced by tirofiban has gradually increased. Still, most of them have thrombocytopenia after the first use. We report one case of very severe thrombocytopenia following the reuse of tirofiban.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case summary<\/jats:title><jats:p>A 65-year-old man of Han nationality, 170\u2005cm in height, 85\u2005kg in weight, and 29.4\u2005BMI, suffered from cerebral infarction 13 years ago and left with right limb movement disorder. Five days before this hospitalization, the patient underwent PCI, and three stents were implanted. After the operation, anti-platelet tirofiban and nadroparin calcium were given, and no thrombocytopenia was found. The patient still retains 80% stenosis due to anterior descending branches and plans to undergo PCI again half a month later. The patient with a history of hypertension, type 2 diabetes, diabetic nephropathy, and cerebral infarction usually took 100\u2005mg of aspirin and 75\u2005mg of clopidogrel, antiplatelet therapy, and had no history of food and drug allergy. One day after discharge, the patient suddenly felt chest tightness and wheezing. The laboratory showed hypersensitivity troponin 2.85\u2005ng\/ml (normal 0\u20130.0268\u2005ng\/ml), and the admission ECG showed ST-T changes in leads I, aVL, V5-V6. On the 6th day of hospitalization, PCI was performed, a stent was implanted in the proximal section of the anterior descending branch opening, and tirofiban(10\u2005ug\/kg, 3\u2005min bolus, then 0.1\u2005ug\/kg\/min) antiplatelet therapy was given after surgery. About 10\u2005min after the tirofiban infusion, the patient suddenly shivered, accompanied by convulsions, accompanied by elevated body temperature (up to 39.4\u00b0C), accompanied by epistaxis and microscopic hematuria. An urgent blood test showed that the platelets dropped to 1\u2009\u00d7\u2009109\/L, tirofiban and aspirin stopped immediately, and the antiplatelet therapy of clopidogrel was retained. After infusion of methylprednisolone sodium succinate and gamma globulin, the patient's platelets gradually recovered, and the patient was successfully discharged seven days later in stable condition.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This case is typical of severe thrombocytopenia caused by reusing tirofiban. This case may provide new insights into: 1. Patients who did not have thrombocytopenia after the first use of tirofiban may still have extremely severe thrombocytopenia after re-exposure to tirofiban. Routine platelet count monitoring and early identification of thrombocytopenia are the essential links. 2. Thrombocytopenia caused by re-exposure to tirofiban may have a faster onset, deeper degree, and slower recovery due to antibodies retained after the first exposure to tirofiban; 3. Platelet transfusions may not be necessary for patients with severe thrombocytopenia; 4. Immunosuppressants help suppress the body's immune response, promote platelet recovery, and can be reduced or discontinued when platelets rise and may be safe; 5. After tirofiban for PCI, continuing the maintenance dose of clopidogrel may be safe if the patient has no significant bleeding events.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2023.1130552","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T05:06:36Z","timestamp":1684472796000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Case report: reuse of tirofiban leads to very severe thrombocytopenia"],"prefix":"10.3389","volume":"10","author":[{"given":"Yuqing","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuchun","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e1371","DOI":"10.4244\/EIJ-D-21-00904","article-title":"Antiplatelet therapy after percutaneous coronary intervention","volume":"17","author":"Angiolillo","year":"2022","journal-title":"EuroIntervention"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/j.jcin.2015.04.031","article-title":"Impact of glycoprotein IIb\/IIIa inhibition in contemporary percutaneous coronary intervention for acute coronary syndromes: insights from the national cardiovascular data registry","volume":"8","author":"Safley","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"key":"B3","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s10557-004-6228-9","article-title":"Repetitive profound thrombocytopenia after treatment with tirofiban: a case report","volume":"18","author":"Eryonucu","year":"2004","journal-title":"Cardiovasc Drugs Ther"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.3390\/jcm9072212","article-title":"Pathophysiology and diagnosis of drug-induced immune thrombocytopenia","volume":"9","author":"Vayne","year":"2020","journal-title":"J Clin Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1111\/j.1538-7836.2006.01829.x","article-title":"Thrombocytopenia associated with the use of GPIIb\/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb\/IIIa inhibitors","volume":"4","author":"Aster","year":"2006","journal-title":"J Thromb Haemost"},{"key":"B6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3969\/j.issn.1000-3614.2021.06.004","article-title":"Analysis on the repeat administration of tirofiban induced severe thrombocytopenia in six patients","volume":"36","author":"Guo","year":"2021","journal-title":"Chin Circ J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.jacc.2021.08.013","article-title":"Bridging antiplatelet therapy after percutaneous coronary intervention: jACC review topic of the week","volume":"78","author":"Sullivan","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"53s","DOI":"10.1378\/chest.127.2_suppl.53S","article-title":"Immune thrombocytopenia caused by glycoprotein IIb\/IIIa inhibitors","volume":"127","author":"Aster","year":"2005","journal-title":"Chest"},{"key":"B9","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1161\/hc3301.094533","article-title":"Abciximab Readministration: results of the ReoPro readministration registry","volume":"104","author":"Tcheng","year":"2001","journal-title":"Circulation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"995","DOI":"10.4065\/83.9.995","article-title":"Survival benefit with concomitant clopidogrel and glycoprotein IIb\/IIIa inhibitor therapy at ad hoc percutaneous coronary intervention","volume":"83","author":"Gumina","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1182\/blood.V100.6.2071","article-title":"Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb\/IIIa","volume":"100","author":"Bougie","year":"2002","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1161\/ATVBAHA.114.303411","article-title":"Targeting integrin and integrin signaling in treating thrombosis","volume":"35","author":"Estevez","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3390\/jcm10040594","article-title":"Pseudothrombocytopenia-A review on causes, occurrence and clinical implications","volume":"10","author":"Lardinois","year":"2021","journal-title":"J Clin Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e495S","DOI":"10.1378\/chest.11-2303","article-title":"Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physicians evidence-based clinical practice guidelines","volume":"141","author":"Linkins","year":"2012","journal-title":"Chest"},{"key":"B15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1161\/atvbaha.120.315445","article-title":"Heparin-Induced thrombocytopenia: a focus on thrombosis","volume":"41","author":"Arepally","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"745","DOI":"10.2165\/00003495-199754020-00009","article-title":"Clopidogrel","volume":"54","author":"Markham","year":"1997","journal-title":"Drugs"},{"key":"B17","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1055\/s-2005-925468","article-title":"Pathogenesis of thrombotic thrombocytopenic purpura: aDAMTS13 deficiency and beyond","volume":"31","author":"Lian","year":"2005","journal-title":"Semin Thromb Hemost"},{"key":"B18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2165\/00003088-200241030-00003","article-title":"Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb\/IIIa receptor antagonist: comparison with the monoclonal antibody Abciximab","volume":"41","author":"Kondo","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1023\/A:1008887708104","article-title":"Drug-Induced thrombocytopenia: is it a serious concern for glycoprotein IIb\/IIIa receptor inhibitors?","volume":"5","author":"Giugliano","year":"1998","journal-title":"J Thromb Thrombolysis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00392-006-0459-7","article-title":"Glycoprotein IIb\/IIIa inhibitor-induced thrombocytopenia: diagnosis and treatment","volume":"96","author":"Said","year":"2007","journal-title":"Clin Res Cardiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1001\/jama.2015.2323","article-title":"Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial","volume":"313","author":"Han","year":"2015","journal-title":"Jama"},{"key":"B22","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/bjh.14423","article-title":"Guidelines for the use of platelet transfusions","volume":"176","author":"Estcourt","year":"2017","journal-title":"Br J Haematol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ijcard.2004.07.014","article-title":"Analysis of bleeding complications associated with glycoprotein IIb\/IIIa receptors blockade in patients with high-risk acute coronary syndromes: insights from the PRISM-PLUS study","volume":"100","author":"Huynh","year":"2005","journal-title":"Int J Cardiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.3389\/fphar.2018.01456","article-title":"A simple clinical Pre-procedure risk model for predicting thrombocytopenia associated with periprocedural use of tirofiban in patients undergoing percutaneous coronary intervention","volume":"9","author":"Yi","year":"2018","journal-title":"Front Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e20402","DOI":"10.1097\/MD.0000000000020402","article-title":"Influences of different dose of tirofiban for acute ST elevation myocardial infarction patients underwent percutaneous coronary intervention","volume":"99","author":"Wang","year":"2020","journal-title":"Medicine (Baltimore)"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1130552\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T05:06:41Z","timestamp":1684472801000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1130552\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,19]]},"references-count":25,"alternative-id":["10.3389\/fcvm.2023.1130552"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1130552","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,19]]},"article-number":"1130552"}}